Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice. 2009

Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho Maklaya 16/10, Moscow 119334, Russia.

Tremendous efforts to produce an efficient vaccine for HIV infection have been unsuccessful. The ability of HIV to utilize sophisticated mechanisms to escape killing by host immune system rises dramatic problems in the development of antiviral therapeutics. The HIV infection proceeds by interaction of coat viral glycoprotein gp120 trimer with CD4(+) receptor of the lymphocyte. Thus this surface antigen may be regarded as a favorable target for immunotherapy. In the present study, we have developed three different strategies to produce gp120-specific response in autoimmune prone mice (SJL strain) as potential tools for production "catalytic vaccine". Therefore (i) reactive immunization by peptidylphosphonate, structural part of the coat glycoprotein, (ii) immunization by engineered fused epitopes of gp120 and encephalogenic peptide, a part of myelin basic protein, and (iii) combined vaccination by DNA and corresponding gp120 fragments incorporated into liposomes were investigated. In the first two cases monoclonal antibodies and their recombinant fragments with amidolytic and gp120-specific proteolytic activities were characterized. In the last case, catalytic antibodies with virus neutralizing activity proved in cell line models were harvested.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D004676 Myelin Basic Protein An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes. Golli-MBP1 Protein,Golli-MBP2 Protein,HOG5 Protein,HOG7 Protein,MBP1 Protein,MBP2 Protein,MBP3 Protein,MBP4 Protein,Myelin Basic Protein, 17.2 kDa Isoform,Myelin Basic Protein, 18.5 kDa Isoform,Myelin Basic Protein, 20.2 kDa Isoform,Myelin Basic Protein, 21.5 kDa Isoform,Myelin Basic Protein, Isoform 1,Myelin Basic Protein, Isoform 2,Myelin Basic Protein, Isoform 3,Myelin Basic Protein, Isoform 4,Myelin Basic Protein, Isoform 5,Myelin Basic Protein, Isoform 6,Myelin Basic Protein, Isoform 7,Golli MBP1 Protein,Golli MBP2 Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D015202 Protein Engineering Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes. Genetic Engineering of Proteins,Genetic Engineering, Protein,Proteins, Genetic Engineering,Engineering, Protein,Engineering, Protein Genetic,Protein Genetic Engineering
D015551 Autoimmunity Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES. Autoimmune Response,Autoimmune Responses,Autoimmunities
D015699 HIV Envelope Protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. Envelope Glycoprotein gp120, HIV,HTLV-III gp120,env Protein gp120, HIV,gp120(HIV),HIV Envelope Glycoprotein gp120,gp120 Envelope Glycoprotein, HIV,HTLV III gp120,gp120, HTLV-III

Related Publications

Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
January 2006, Biochemistry,
Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
November 2004, Virology,
Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
January 2000, Chemical immunology,
Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
January 2006, Annual review of immunology,
Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
January 1996, Journal of biological regulators and homeostatic agents,
Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
August 1997, Clinical and experimental immunology,
Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
November 2021, Journal of the International AIDS Society,
Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
June 1994, Journal of immunology (Baltimore, Md. : 1950),
Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
March 1994, Journal of neuroscience research,
Oxana M Durova, and Ivan I Vorobiev, and Ivan V Smirnov, and Andrew V Reshetnyak, and Georgy B Telegin, and Olga G Shamborant, and Nadezda A Orlova, and Dmitry D Genkin, and Andrew Bacon, and Natalia A Ponomarenko, and Alain Friboulet, and Alexander G Gabibov
March 2008, Virology,
Copied contents to your clipboard!